Analyst Maintains Market Outperform Rating for Pharvaris with Increased Price Target
On January 23, 2024, JMP Securities analyst Jonathan Wolleben expressed his optimistic stance on Pharvaris (NASDAQ: PHVS) by maintaining a ...
© 2024 Stocks Today
Tag: PHVS
Pharvaris Receives FDA Approval to Proceed with Clinical Trials for Deucrictibant A Promising Step Towards Treating Hereditary Angioedema
As of January 22, 2024, an exciting announcement has been made regarding Pharvaris' investigational new drug application for deucrictibant. The ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools
-
The Future of Secure Communications: How Quantum-Resistant Encryption is Revolutionizing Wireless Technology
-
The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions
-
Unlocking Potential: How Recent Acquisitions in the Battery Technology Sector Are Reshaping the Energy Landscape